Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Prandin
Prandin 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-108711 · Präparat HOS-093055
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2817–3891 im Abschnitt
Wechselwirkungen · Kineret
Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 8
HOS-108743 · Präparat HOS-093075
Cytochrome P450 Substrates
The formation of CYP450 enzymes is suppressed by increased levels of cytokines (e.g., IL-1) during
chronic inflammation. Thus, it may be expected that for an IL-1 receptor antagonist, such as anakinra,
the formation of CYP450 enzymes could be normalized during treatment. This would be clinically
relevant for CYP450 substrates with a narrow therapeutic index (e.g. warfarin and phenytoin). Upon
start or end of Kineret treatment in patients on these types of medicinal products, it may be relevant to
consider therapeutic monitoring of the effect or concentration of these products and the individual dose
of the medicinal product may need to be adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-15T12:46:00Z · SHA-256 53a0a98f576dc350e42d4cc85e11cf9eeb4b97cf7707add713e0c1a596152e85 · Passage 9950adeb7b4496ab06c21fb6e6726a65b93abc3dd4d6b5704685fda5493496fc · Zeichen 873–1556 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 15–16
HOS-108886 · Präparat HOS-093083
15
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to P-gp inhibition considered when a DOAC
by lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4,
including dabigatran etexilate and
edoxaban, is co-administered with
Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with
moderately decreased due to Kaletra.
CYP2C9 and CYP2C19 induction
by lopinavir/ritonavir. Phenytoin levels should be
monitored when co-administering
Lopinavir: with Kaletra.
Concentrations are decreased due
to CYP3A induction by When co-administered with
phenytoin. phenytoin, an increase of Kaletra
dosage may be envisaged. Dose
adjustment has not been evaluated
in clinical practice.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir.
Carbamazepine and phenobarbital
Lopinavir: levels should be monitored when
Concentrations may be decreased co-administering with Kaletra.
due to CYP3A induction by
carbamazepine and phenobarbital. When co-administered with
carbamazepine or phenobarbital, an
increase of Kaletra dosage may be
envisaged. Dose adjustment has
not been evaluated in clinical
practice
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage a45fdd8825462561a02993489236d84d7e773cdb05b58085ed2d9feb61b50710 · Zeichen 23538–26612 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-109010 · Präparat HOS-093083
For patients who have completed the
ramp-up phase and are on a steady
daily dose of venetoclax, reduce the
venetoclax dose by at least 75%
when used with strong CYP3A
inhibitors (refer to the venetoclax
SmPC for dosing instructions).
Patients should be closely monitored
for signs related to venetoclax
toxicities.
Anticoagulants
Warfarin Warfarin: It is recommended that INR
Concentrations may be affected (international normalised ratio) be
when co-administered with monitored.
lopinavir/ritonavir due to
CYP2C9 induction.
Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban and
AUC: ↑ 153% Kaletra may increase rivaroxaban
(Ritonavir 600 mg twice Cmax: ↑ 55% exposure which may increase the risk
daily) Due to CYP3A and P-gp of bleeding.
inhibition by lopinavir/ritonavir. The use of rivaroxaban is not
recommended in patients receiving
concomitant treatment with Kaletra
(see section 4.4).
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to Pgp inhibition by considered when a DOAC
lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4, including
dabigatran etexilate and edoxaban, is
co-administered with Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with Kaletra.
moderately decreased due to Phenytoin levels should be monitored
CYP2C9 and CYP2C19 induction when co-administering with Kaletra.
by lopinavir/ritonavir. When co-administered with
phenytoin, an increase of Kaletra
Lopinavir: dosage may be envisaged. Dose
Concentrations are decreased due adjustment has not been evaluated in
to CYP3A induction by clinical practice.
phenytoin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): venetoclax (HOS-086143) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 092834c32db98766e5109cb3ff4d0c6a8ea77721ca8064bfcdfc67660162c006 · Zeichen 20961–24616 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52–53
HOS-109011 · Präparat HOS-093083
52
Kaletra must not be administered
once daily in combination with
phenytoin.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital
levels should be monitored when
Lopinavir: co-administering with Kaletra.
Concentrations may be decreased When co-administered with
due to CYP3A induction by carbamazepine or phenobarbital, an
carbamazepine and phenobarbital. increase of Kaletra dosage may be
envisaged. Dose adjustment has not
been evaluated in clinical practice.
Kaletra must not be administered
once daily in combination with
carbamazepine and phenobarbital.
Lamotrigine and Lamotrigine: Patients should be monitored closely
Valproate AUC: ↓ 50% for a decreased VPA effect when
Cmax: ↓ 46% Kaletra and valproic acid or valproate
Cmin: ↓ 56% are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 7ab99d1352f73d28a2d94a0c91058c6dc39f0bd1e0fb1d81b22f720114b89a89 · Zeichen 24661–26644 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 87–88
HOS-109085 · Präparat HOS-093083
87
Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban
AUC: ↑ 153% and Kaletra may increase
(Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may
daily) Due to CYP3A and P-gp increase the risk of bleeding.
inhibition by lopinavir/ritonavir. The use of rivaroxaban is not
recommended in patients receiving
concomitant treatment with Kaletra
(see section 4.4).
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to Pgp inhibition by considered when a DOAC
lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4, including
dabigatran etexilate and edoxaban,
is co-administered with Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with
moderately decreased due to Kaletra.
CYP2C9 and CYP2C19 induction Phenytoin levels should be
by lopinavir/ritonavir. monitored when co-administering
with Kaletra.
Lopinavir: When co-administered with
Concentrations are decreased due phenytoin, an increase of Kaletra
to CYP3A induction by dosage may be envisaged. Dose
phenytoin. adjustment has not been evaluated
in clinical practice.
Kaletra must not be administered
once daily in combination with
phenytoin.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital
levels should be monitored when
Lopinavir: co-administering with Kaletra.
Concentrations may be decreased When co-administered with
due to CYP3A induction by carbamazepine or phenobarbital, an
carbamazepine and phenobarbital. increase of Kaletra dosage may be
envisaged. Dose adjustment has not
been evaluated in clinical practice.
Kaletra must not be administered
once daily in combination with
carbamazepine and phenobarbital.
Lamotrigine and Lamotrigine: Patients should be monitored
Valproate AUC: ↓ 50% closely for a decreased VPA effect
Cmax: ↓ 46% when Kaletra and valproic acid or
Cmin: ↓ 56% valproate are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0668c273c88d1ae41827a69ac1504dff6543bd6b0d2a053e402140143e6219fb · Zeichen 22156–26627 im Abschnitt
Wechselwirkungen · Replagal
Replagal 1 mg/ml concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 4–5
HOS-109141 · Präparat HOS-093103
4
carbamazepine, phenytoin, and gabapentin) were administered concurrently to most patients without
any evidence of interaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) gabapentin (HOS-090745) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T11:02:00Z · SHA-256 dcaf8d70406379842b10712a63f58455ab2c0f96e49a183cadc2b152a7bb72f1 · Passage a8ebeee1ed0a87c0d725caf19dcc9d37d642dff2db07debd33af3b54d8dcdb03 · Zeichen 435–564 im Abschnitt
Wechselwirkungen · Axura
Axura 10 mg film-coated tablets Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets Axura 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-109260 · Präparat HOS-093165
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:43:00Z · SHA-256 f6f4d5233129ccc09d7b126c13573858c875ee45f87e7bb2987c68026bf63a30 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Wechselwirkungen · Axura
Axura 5 mg/pump actuation, oral solution · Abschnitt 4.5 · PDF-Seite 15
HOS-109291 · Präparat HOS-093165
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:43:00Z · SHA-256 f6f4d5233129ccc09d7b126c13573858c875ee45f87e7bb2987c68026bf63a30 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Wechselwirkungen · Cancidas (previously Caspofungin MSD)
CANCIDAS 50 mg powder for concentrate for solution for infusion CANCIDAS 70 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-109316 · Präparat HOS-093179
Rifampicin caused a 60 % increase in AUC and 170 % increase in trough concentration of
caspofungin on the first day of co-administration when both medicinal products were initiated together
in healthy adult volunteers. Caspofungin trough levels gradually decreased upon repeated
administration. After two weeks’ administration rifampicin had limited effect on AUC , but trough
levels were 30 % lower than in adult subjects who received caspofungin alone. The mechanism of
interaction could possibly be due to an initial inhibition and subsequent induction of transport proteins.
A similar effect could be expected for other medicinal products that induce metabolic enzymes.
Limited data from population pharmacokinetics studies indicate that concomitant use of caspofungin
with the inducers efavirenz, nevirapine, rifampicin, dexamethasone, phenytoin, or carbamazepine may
result in a decrease in caspofungin AUC. When co-administering inducers of metabolic enzymes, an
increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should be
considered in adult patients (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): caspofungin (HOS-109306) carbamazepine (HOS-085618) dexamethasone (HOS-084535) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T16:40:00Z · SHA-256 6dd11a424b362e655ce61e4c49586bb6e658af1133d504982e2602258f5f83f7 · Passage c5e8ec4138eb43633aaa64f4543ed03cde7127a4cc4272212397a4000cb15545 · Zeichen 2098–3211 im Abschnitt
Wechselwirkungen · Cancidas (previously Caspofungin MSD)
CANCIDAS 50 mg powder for concentrate for solution for infusion CANCIDAS 70 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-109318 · Präparat HOS-093179
In paediatric patients, results from regression analyses of pharmacokinetic data suggest that
co-administration of dexamethasone with caspofungin may result in clinically meaningful reductions
in caspofungin trough concentrations. This finding may indicate that paediatric patients will have
similar reductions with inducers as seen in adults. When caspofungin is co-administered to paediatric
patients (12 months to 17 years of age) with inducers of drug clearance, such as rifampicin, efavirenz,
nevirapine, phenytoin, dexamethasone, or carbamazepine, a caspofungin dose of 70-mg/m2 daily (not
to exceed an actual daily dose of 70 mg) should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): caspofungin (HOS-109306) carbamazepine (HOS-085618) dexamethasone (HOS-084535) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T16:40:00Z · SHA-256 6dd11a424b362e655ce61e4c49586bb6e658af1133d504982e2602258f5f83f7 · Passage 2b38d9d64ebe68889c50178e2fa7dc0ddad8f54c99fefad6f8ee618fb5bd6dc9 · Zeichen 3434–4092 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-109360 · Präparat HOS-093187
The effect of enzyme induction has not been studied. The metabolism of valdecoxib may increase
when coadministered with enzyme inducers such as rifampicin, phenytoin, carbamazepine, or
dexamethasone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) dexamethasone (HOS-084535) valdecoxib (HOS-109357) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 3127288617c2ae1665375c41371442dad037d7cab0ec9c2247bb04d1f71f8673 · Zeichen 3494–3693 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-109365 · Präparat HOS-093187
Plasma exposure of omeprazole (CYP 2C19 substrate) 40 mg once daily was increased by 46%
following administration of valdecoxib 40 mg twice daily for 7 days, while the plasma exposure to
valdecoxib was unaffected. These results indicate that although valdecoxib is not metabolised by
CYP2C19, it may be an inhibitor of this isoenzyme. Therefore, caution should be observed when
administering Dynastat with medicinal products known to be substrates of CYP2C19 (e.g. phenytoin,
diazepam, or imipramine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) diazepam (HOS-085904) valdecoxib (HOS-109357) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 1174ed6865ef4da5a1bc4cf18b53d520c40718ae93707fd5f081a1005f418d36 · Zeichen 4177–4678 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 23
HOS-109407 · Präparat HOS-093187
The effect of enzyme induction has not been studied. The metabolism of valdecoxib may increase
when coadministered with enzyme inducers such as rifampicin, phenytoin, carbamazepine or
dexamethasone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) dexamethasone (HOS-084535) valdecoxib (HOS-109357) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 562b61d7bc2cbcaffb088c1e1a84457fc39b42413146349b6d6a0b9301f14684 · Zeichen 3496–3694 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 23
HOS-109409 · Präparat HOS-093187
Plasma exposure of omeprazole (CYP 2C19 substrate) 40 mg once daily was increased by 46%
following administration of valdecoxib 40 mg twice daily for 7 days, while the plasma exposure to
valdecoxib was unaffected. These results indicate that although valdecoxib is not metabolised by
CYP2C19, it may be an inhibitor of this isoenzyme. Therefore, caution should be observed when
administering Dynastat with medicinal products known to be substrates of CYP2C19 (e.g. phenytoin,
diazepam, or imipramine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) diazepam (HOS-085904) valdecoxib (HOS-109357) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 1174ed6865ef4da5a1bc4cf18b53d520c40718ae93707fd5f081a1005f418d36 · Zeichen 4178–4679 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-109445 · Präparat HOS-093201
Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔
[CYP3A4 inhibitor]
The effect of voriconazole on
either erythromycin or
azithromycin is unknown.
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax 69% unless the benefit outweighs the
300 mg QD Voriconazole AUC 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUC 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUC 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
voriconazole.
Voriconazole Cmax 104%
Voriconazole AUC 87%
Rifampicin (600 mg QD) Voriconazole Cmax 93% Contraindicated (see section
[potent CYP450 inducer] Voriconazole AUC 96% 4.3)
Anti-cancer agents
Glasdegib Although not studied, voriconazole If concomitant use cannot be
[CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG
concentrations of glasdegib and monitoring is recommended (see
increase risk of QTc prolongation. section 4.4).
Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is
[CYP3A4 substrate] may increase tretinoin recommended during treatment
concentrations and increase risk of with voriconazole and after its
adverse reactions (pseudotumor discontinuation.
cerebri, hypercalcaemia).
11
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) azithromycin (HOS-088112) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) erythromycin (HOS-084514) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92969ff5c9d1e7ffb4a2f7eaf265abd9d2899e7061ac52ea8adefc4d660b4316 · Zeichen 4932–11582 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-109458 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
12
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) indinavir (HOS-084518) protease (HOS-085623) glucose (HOS-088412) lead (HOS-085592) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) ritonavir (HOS-084521) terfenadine (HOS-085607) phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage c43ce720ce152b6ffc284ecb767edcbe81187c3aba91372adac27d1baca516f9 · Zeichen 11584–14886 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 43–44
HOS-109538 · Präparat HOS-093201
43
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenprocoumon (HOS-091031) prothrombin (HOS-085093) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) mephobarbital (HOS-109457)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5ae9bbe0daf742daaf2a160c7d91f0c8d54a2ad8a7e98684c6f63198d04c2a65 · Zeichen 10221–11996 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 44
HOS-109539 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) glucose (HOS-088412) lead (HOS-085592) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 14b5c619fb8c5577b3bdbf58510949a3e586575fc62bef1b01af9d0042239698 · Zeichen 11998–14502 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75–76
HOS-109603 · Präparat HOS-093201
75
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) vinblastine (HOS-086220) vincristine (HOS-086219) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f6b81055f3c718e14857cfd38d70a912e61bf8acd5f789552e442ecbfbe65b67 · Zeichen 7792–11614 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.